SCR1693

has cognitive enhancing activity; structure in first source

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

1.	Hyperhomocysteinemia 01/01/2014 - "In this study, we tested the effects of a synthesized juxtaposition (named SCR1693) composed of an acetylcholinesterase inhibitor (AChEI) and a calcium channel blocker (CCB) on the hyperhomocysteinemia (HHcy)-induced AD rat model, and found that SCR1693 remarkably improved the HHcy-induced memory deficits and preserved dendrite morphologies as well as spine density by upregulating synapse-associated proteins PSD95 and synapsin-1. "
2.	Memory Disorders (Memory Loss) 01/01/2014 - "In this study, we tested the effects of a synthesized juxtaposition (named SCR1693) composed of an acetylcholinesterase inhibitor (AChEI) and a calcium channel blocker (CCB) on the hyperhomocysteinemia (HHcy)-induced AD rat model, and found that SCR1693 remarkably improved the HHcy-induced memory deficits and preserved dendrite morphologies as well as spine density by upregulating synapse-associated proteins PSD95 and synapsin-1. "

1.	Proteins (Proteins, Gene)
2.	Cholinesterase Inhibitors (Anticholinesterases)
3.	Calcium Channel Blockers (Blockers, Calcium Channel)